AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06283810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychotherapy of interpersonal relationships
Description: Group KIPT will be 1 session per week and each session will last 90 minutes. There will be 7 sessions in total, and a completion session will be held 2 weeks after the completion of Group KIPT. In order for the students in G1 to understand which group they are in, they will also be informed about the points to be considered regarding laughter therapy. An unstructured laughter intervention will be applied at the beginning or at the end of the sessions in which group IPT is applied.~Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week (intervention interval), 8th week (end of intervention) and 12th week (long-term effect). Within the scope of work packages 3 and 4, KIPT application and other measurements will be made.
Study NCT06283810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laughter therapy
Description: Laughter therapy is 1 session per week and each session will last 40 minutes. A total of 8 sessions will continue. Each session will start with warm-up and deep breathing exercises and will continue with applause and childish games. Afterwards, games specific to each session will be added. Unstructured interviews will be conducted with G2 at the beginning or at the end of the session, suggesting that they were subjected to group CIPT. Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week (intervention interval), 8th week (end of intervention) and 12th week (long-term effect) when the interviews start.
Study NCT06283810 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Plasebo
Description: After the initial data are collected, unstructured interviews about the interpersonal relationships of the person will be conducted by conducting individual interviews with each student for 2-3 sessions at the beginning of the study in case the student does not understand which group he/she is in. Afterwards, unstructured random interviews and laughter intervention will be conducted for a total of 8 sessions lasting 40 minutes, 1 session per week. Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week, 8th week and 12th week (long-term effect) when the interviews start.
Study NCT06067100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol and Mometasonefluroate (low dose)
Description: Participants are administered 125 µg indacaterol + mometasonefluroate
Study NCT06067100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants are administered placebo
Study NCT06067100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol and Mometasonefluroate (high dose)
Description: Participants are administered 500 µg indacaterol + mometasonefluroate
Study NCT06017609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-861 Capsules
Description: Active drug capsules containing JTT-861
Study NCT06017609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Capsules
Description: Placebo capsules matching in appearance to the active drug capsules
Study NCT04787549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality exergames
Description: A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for exergames using fully immersive virtual reality under the assistance of an occupational therapist.
Study NCT06497062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sonrotoclax
Description: Orally once daily, on D5-14. A 4-day dose ramp-up is required for the first induction. The dosing regimen will be determined in the Safety Run-in phase.~If a second induction is needed, dose ramp-up is not required. In the consolidation therapy phase, subjects in the group with favorable risk and MRD negative do not need to receive Sonrotoclax treatment, and subjects in the group with favorable risk and MRD positive, or with intermediate and adverse risk will receive sonrotoclax on D1-7 at the target dose determined in the safety run-in phase, dose ramp-up is not required.~In the maintenance therapy phase, subjects will receive once daily sonrotoclax on D1-14 at the target dose determined in the safety run-in phase.
Study NCT06497062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin/daunorubicin
Description: idarubicin: On D1-3, intravenously, 10 mg/m\^2 for subjects aged \<60 years, 6 mg/m\^2 for subjects aged ≥60 years daunorubicin: On D1-3, intravenously, 60 mg/m\^2 for subjects aged \<60 years, 40 mg/m\^2 for subjects aged ≥60 years
Study NCT06497062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: In induction therapy phase: intravenously, 100 mg/m\^2 on D1-7. In consolidation therapy phase: subjects with favorable-risk and MRD negative will receive cytarabine intravenously at 2 g/m\^2/q12h for those aged \<60 years, at 1g/m\^2/q12h for those ≥60 years on D1-3 or 3+7 regimen, and subjects with favorable-risk and MRD positive or intermediate or adverse-risk will receive cytarabine intravenously at 1 g/m\^2/d q12h on D1-3(in combination with sonrotoclax).
Study NCT06497062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2, subcutaneously, once daily, on D1-7
Study NCT06497062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allo-HSCT
Description: Per standard of procedure
Study NCT05834088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release techniques
Description: 12 treatment sessions will be given in 12 weeks
Study NCT05834088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial release techniques
Description: 12 treatment sessions will be given in 12 weeks
Study NCT05834088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thiele massage
Description: 12 treatment sessions will be given in 12 weeks
Study NCT05540340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics
Description: Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan, for PK testing. The first four time points are +/- 2 min and the last two time points are +/- 5 minutes.
Study NCT05540340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics
Description: Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan to determine the actual AUC achieved using the population PK.
Study NCT06657352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ACS Topical Treatment Group
Description: The topical group applied the ACS cream to the face twice daily (morning and night) for 4 weeks.
Study NCT05767658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Brain Development and Parent-Child Relationships
Description: Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for early brain development and parent-child interactions (control intervention) and b) an online community and social network of other pregnant WIC clients and new parents.
Study NCT05732831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG462
Description: TNG462, a selective PRMT5 inhibitor, will be administered orally
Study NCT03834818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMPAS Participants
Description: The schedule of events for this study are as follows:~Day 1 Pre-Surgery:~* Download the Medable App~* Register to the study~* Validated Questionnaires~* Active Task~Every Day~* 9:00 a.m. Daily Questions~* 9:00 p.m. Daily Questions~Outcome Surveys and Active Task:~* Day 1 Pre-Surgery~* 1-Week Post Operation~* 2-Weeks Post Operation~* 1-Month Post Operation~* 3-Months Post Operation~* 6-Months Post Operation
Study NCT05009069 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: Weeks 1-5: 45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.
Study NCT05009069 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Weeks 1-5: 45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.
Study NCT06657352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Topical Placebo Group
Description: The topical group applied the cream (without ACS) to the face twice daily (morning and night) for 4 weeks.
Study NCT06657352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Treatment + Topical Treatment Group
Description: The combination group used both the topical and oral ACS products for 12 weeks.
Study NCT06657352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ACS Oral Treatment Group
Description: The oral group ingested one ACS capsule twice daily after breakfast and dinner for 12 weeks.
Study NCT06657352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo Group
Description: The oral group ingested one capsule (without ACS) twice daily after breakfast and dinner for 12 weeks.
Study NCT05732831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: An anti PD-1 antibody, will be administered intravenously
Study NCT06657352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral Treatment + Topical Placebo Group
Description: The combination group used both the topical and oral products without ACS for 12 weeks.
Study NCT06408181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 162 mg
Description: Aspirin is a nonsteroidal anti-inflammatory drug.
Study NCT06408181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin 81mg
Description: Aspirin is a nonsteroidal anti-inflammatory drug.
Study NCT06029257 — intervention group
Intervention type: DRUG
Intervention: Tildrakizumab
Description: As provided in real-world clinical practice.
Study NCT06605651 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Staphylococcus aureus Bacteriophages (PP1493 and PP1815) intra-articular injection with 0.9% NaCl solution
Description: Three intra-articular injections during and/or following DAIR procedure
Study NCT06605651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl solution
Description: Three intra-articular injections during and/or following DAIR procedure
Study NCT06657651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant placement with dentin-derived membrane
Description: immediate implant placement with dentin-derived membrane and allograft in mandibular molar area
Study NCT06657651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant with extended platelet rich fibrin membrane
Description: immediate implant with extended platelet rich fibrin membrane and allograft in mandibular molar area
Study NCT06662240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The effect of vibration anesthesia on pain, ecchymosis and comfort level in subcutaneous heparin injection
Description: The patient in the experimental group received one vibrating injection and one non-vibrating injection into the abdomen. The patient in the control group received 2 standard subcutaneous injections in the abdomen without vibration.
Study NCT05362773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGD024
Description: MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes.
Study NCT04923542 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: Patients will receive single session SRS to intact brain metastases and post-operative cavities. For intact brain metastases, this will be 15 Gy to lesions between 31-40 mm, 18 Gy to 21- 30 mm, and 24 Gy to lesions measuring ≤ 20 mm.
Study NCT06611345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields
Description: Tumor treating fields will be used each day.
Study NCT06611345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg will be administrated via Intravenous (IV) infusion Once Every 3 weeks (Q3W) on day 1 of each cycle for up to 8 cycles. And then 1500 mg Once Every 4 weeks (Q4W) on day 1 of each cycle until confirmed progressive disease (PD).
Study NCT06611345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
Study NCT06611345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
Study NCT04923542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib is an orally administered selective small-molecule inhibitor of CDK4 and CDK6 that is 14 times more potent against CDK4 than CDK6 in enzymatic assays that is approved for the treatment of advanced or metastatic breast cancers. Abemaciclib will be administered at a dose of 150 mg twice daily.
Study NCT04923542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Abemaciclib will be administered with standard of care endocrine therapy. Endocrine therapy can consist of fulvestrant or an aromatase inhibitor. Dosing of concurrent endocrine therapy with abemaciclib should follow standard dosing and safety guidelines.
Study NCT06068543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epigallocatechin-3-Gallate (EGCG)
Description: 800mg Epigallocatechin-3-Gallate (EGCG)
Study NCT06068543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose (MCC)
Description: 800mg microcrystalline cellulose (MCC)
Study NCT06068543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (Vitamin C)
Description: 250mg Ascorbic Acid (Vitamin C) taken one time daily for 12 weeks
Study NCT06068543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ascorbic Acid (Vitamin C)
Description: 250mg Ascorbic Acid (Vitamin C) taken one time daily for 12 weeks
Study NCT06543732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Return to work program
Description: The eHealth modules focus on psychoeducation, perceptions of return to work based on a personal plan including problem-solving exercises, relapse prevention, and continuous monitoring. If needed, followed by the participatory approach, a stepwise, collaborative approach to analyse and solve bottlenecks to develop a consensus-based plan for return to work.
Study NCT05586360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: Simvastatin 40mg taken orally daily for 8 weeks
Study NCT05894005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Virtual Reality (IVR)
Description: * Group A IVR: Students will be first taken to the anesthesia lounge. Here the students will receive IVR instructions on how to navigate the route (i.e. they will watch a 360-degree video using Oculus VR headset). Then the students will be assessed with an observed walkthrough of the route~* Group B 2D video: Students will be first taken to the anesthesia lounge. Students will receive 2D video instruction on how to navigate the route by watching a normal 2D video using a desktop computer screen. Then the students will be assessed with an observed walkthrough of the route.
Study NCT04551131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given orally (PO) or per nasogastric tube (NGT) twice a day for 8 weeks
Study NCT04551131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given intravenously (IV) or orally (PO) twice a day for 8 weeks
Study NCT04551131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given intravenously (IV) once a week for 8 weeks
Study NCT05009069 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Weeks 1-5: Capecitabine 825 mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.
Study NCT05009069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Weeks 1-5: Capecitabine 825 mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.
Study NCT05009069 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluorouracil
Description: Weeks 1-5: fluorouracil (5-FU) 225 mg/m\^2 intravenously (IV) over 24 hours 5 days/week during radiotherapy.
Study NCT05009069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Weeks 1-5: fluorouracil (5-FU) 225 mg/m\^2 intravenously (IV) over 24 hours 5 days/week during radiotherapy.
Study NCT05009069 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atezolizumab
Description: Weeks 8, 11 and 14: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle for 3 cycles.
Study NCT05009069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Weeks 8, 11 and 14: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle for 3 cycles.
Study NCT05009069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Weeks 8, 11 and 14: Tiragolumab 600 mg IV on Day 1 of each 21-day cycle for 3 cycles.
Study NCT05726903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-subQ Provera Injectable Product
Description: SC Injection at Home
Study NCT04086485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177-DOTATATE
Description: Lu-177-DOTATATE will be given by IV every 8 (+/-2) weeks for a total of 4 administrations
Study NCT04086485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is given as a pill taken orally and is to be taken twice a day, starting from 2 days before the first administration of Lu-177-DOTATATE until 4 weeks after the last administration
Study NCT04920253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study Device Debridement
Description: debritom+ water jet debridement
Study NCT04920253 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOC Debridement
Description: Sharp Scalpel
Study NCT03958019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RESTORE II Program
Description: Detailed in arm description
Study NCT04086485 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ga dotatate scanning
Description: Ga68-DOTATATE PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.
Study NCT04086485 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG-PET scanning
Description: F18-FDG PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.
Study NCT04086485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino Acid infusion
Description: Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection. The AA infusion will begin at least 30-60 minutes prior to injection of Lu-177-DOTATATE and will continue during and after the Lutathera infusion until the entire prescribed amount is infused.
Study NCT06662344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Oral-esophageal Tube Feeding
Description: The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
Study NCT05211635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: One capsule daily for 84 days
Study NCT05211635 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule daily for 84 days
Study NCT05561842 — intervention group
Intervention type: PROCEDURE
Intervention: mHealth US-breast biopsy
Description: During this study, women will undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.
Study NCT05971147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Participants in this group will receive 5g fish oil with high EPA and DHA content per day
Study NCT06123650 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitve transcranial magnetic stimulation
Description: The Magstim Rapid2 magnetic stimulator system (Model P/N 3576-23-09, Magstim Company, Whitland, UK) was used to deliver rTMS electrical currents via a figure of 8 coil applied to the scalp against the targeted contralesional motor  Hot spot , at a depth of approximately 1 cm . The inhibitory rTMS will be applied to the intact cerebral hemisphere at 1 Hz with a train of 1200 for 5 consecutive days.
Study NCT06123650 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham transcranial magnetic stimulation
Description: Repetitive TMS via a sham Magstim coil (identical appearance and noise, but no active stimulation). Identical stimulation schedules as patients in study group.